

NOV 28 2003

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/07/2006. GPO 2001-000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTQ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.		Complete if Known	
Substitute for form 1449/PTO		Application Number	10/632,187
		Filing Date	July 30, 2003
		First Named Inventor	Jurgen Engel et al.
		Art Unit	1614
		Examiner Name	TBA
		Attorney Docket Number	103832-477-NP
Sheet	1	of	2

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
JMM	1	WO	00/33917	06-15-2000	Max-Delbrück-Centrum		
	2	WO	02/066019 A2	08-29-2002	Novartis AG		
/	3	WO	03/05522 A1	07-10-2003	Pharmacia Italia Spa		

Examiner Signature  **Date Considered** **10-26-04**

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹**Applicant's unique citation designation number (optional). **²**See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **³**Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴**For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵**Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **⁶**Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number 103832-477-NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>CM</i>	4	THILO SPRUB, GUNTHER BERNHARDT, HELMUT SCHOENENBERGER and JURGEN ENGEL, Antitumor activity of miltfosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models; J Cancer Res Clin Oncol (1993) 119:142-149 (XP-000905599)	
	5	P. HILGARD, J. STEKAR, T. KLENNER, G. NOSSNER, B. KUTSCHER, and J. ENGEL; Heterocyclic Alkylphospholipids With an Improved Therapeutic Range; Advances In Experimental Medicine and Biology, United States (1996), 157-164 (XP-002256712)	
	6	J. STEKAR, P. HILGARD and T. KLENNER; Opposite Effect of Miltfosine on the Antineoplastic Activity and Haematological Toxicity of Cyclophosphamide; Eur F Cancer, Vol. 31A, No. 3, pp. 372-374, 1995 (XP-002256713)	
	7	MILKA C. GEORGIEVA, SPIRO M. KONSTANTINOV, MARGARIT TOPASHKA-ANCHEVA, MARTIN R. BERGER; Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells; Cancer Letters 182 (2002) 163-174 (XP-002256714)	
	8	D BERKOVIC, EAM FLEER, J BREASS, J PFORTNER, E SCHLEYER and W HIDDENMANN; The influence of 1-B-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells; Leukemia (1997) 11, 2079-2086 (XP-002256715)	
	9	SHOJI M.; RAYNOR R.L.; FLEER E.A.; EIBL H.; VOGLER W.R.; KUO J.F.; Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells; Journal Article (Feb. 1991) Vol. 26, No. 2, 145-149 (XP-002256716)	
<i>CM</i>	10	Copy of International Search Report	

Examiner Signature	<i>CM</i>	Date Considered	10-26-04
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.